Clinical Trial Update: A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of sintilimab and anlotinib in metastatic non-small cell lung cancer after a prior PD-1 inhibitor has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: NSCLC | Phase 2 | Status: COMPLETED